
Oncocyte Corp (IMDX) Stock Forecast & Price Target
Oncocyte Corp (IMDX) Analyst Ratings
Bulls say
Insight Molecular Diagnostics Inc. has a promising outlook due to the potential expansion of its addressable market by 10-20% through the introduction of new testing indications for immunosuppression and rejection monitoring, currently under evaluation with its GraftAssure RUO technology. The company's focus on advancing its portfolio of diagnostic tests for organ transplant monitoring and cancer positions it for strong long-term revenue growth. Key drivers of potential upside include upcoming clinical data releases, favorable updates to NCCN guidelines, and faster-than-anticipated revenue growth.
Bears say
Insight Molecular Diagnostics Inc. is experiencing a significant decline in gross margin, dropping to 53.5% from 67.6% in the previous quarter, reflecting challenges in maintaining profitability despite being above internal estimates. Furthermore, while cash burn has decreased sequentially, the company's anticipated earnings per share (EPS) for 2025 have been revised downward to ($1.11), indicating ongoing financial struggles. The risks associated with this outlook include slow physician adoption of new diagnostic tests, potential delays in insurer coverage and reimbursement, and the possibility of dilutive equity offerings, all of which may hinder the company's growth prospects and financial stability.
This aggregate rating is based on analysts' research of Oncocyte Corp and is not a guaranteed prediction by Public.com or investment advice.
Oncocyte Corp (IMDX) Analyst Forecast & Price Prediction
Start investing in Oncocyte Corp (IMDX)
Order type
Buy in
Order amount
Est. shares
0 shares